Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nexavar Survival Study In Asia-Pacific Patients With Liver Cancer Halted Early

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III study found that sorafenib significantly improved overall survival and progression-free survival in patients with hepatocellular carcinoma.

You may also be interested in...



Bayer/Onyx Submit Nexavar sNDA For Liver Cancer

Filing is based on halted Phase III trial showing overall survival of 44 percent in patients with hepatocellular carcinoma treated with sorafenib.

Bayer/Onyx’ Nexavar Approved For Kidney Cancer

FDA’s full approval of the oncologic indicates sorafenib for broad use by all patients with advanced renal cell carcinoma.

Biohaven Shoots For Oral CGRP Leadership As Nurtec ODT Gains Momentum

The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel